Fujirebio Diagnostics Acquires CanAg Diagnostics

(Malvern, PA, USA), an in vitro diagnostics company, has acquired CanAg Diagnostics AB (Gothenburg, Sweden), a biotechnology company. The union of the two companies in the field of serum tumor markers is designed to result in increased customer offerings and expanded distribution channels to the market. No financial details were provided.

"CanAg Diagnostics possesses outstanding scientific depth and research and development capabilities, strong brand recognition, and long-standing, positive relationships with major diagnostics companies worldwide,” said Paul Touhey, president and COO of Fujirebio Diagnostics. "The combination of the two companies allows us to leverage technical and scientific resources of both organizations to more effectively and efficiently develop new, innovative assays in the field of cancer care.”

Fujirebio Diagnostics develops tumor marker assays and specializes in the clinical development, manufacture, and commercialization of in vitro diagnostic products for the management of human disease states, with an emphasis on oncology. It is currently developing a series of diagnostic products to help doctors detect and monitor bladder, lung, and ovarian cancer. Fujirebio Diagnostics has a worldwide distribution network. Formerly called Centocor Diagnostics, the company was acquired by Fujirebio, Inc. (Tokyo, Japan), in 1998.

CanAg Diagnostics is focused on the development of immunologic reagents such as monoclonal antibodies against biochemical markers of disease, and aims to use these reagents in the development of laboratory tests.



Related Links:
Fujirebio Diagnostics
CanAg Diagnostics